Review



anti phospho shp1 tyr564  (Cell Signaling Technology Inc)


Bioz Verified Symbol Cell Signaling Technology Inc is a verified supplier
Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    Cell Signaling Technology Inc anti phospho shp1 tyr564
    a, LPS-induced (100 ng/ml) <t>SHP1</t> Tyr536, <t>Tyr564</t> and Ser591 phosphorylation in iBMDMs over a time course of 2 h in iBMDMs pre-treated with DMSO or SCA1 (50 μM) for 3 h. Immunoblots shown are representative of three independent experiments. b , LPS-induced (100 ng/ml) STAT3 Tyr705 and Ser727 phosphorylation in iBMDMs over a time course of 2 h in iBMDMs pre-treated with DMSO or SCA1 (50 μM) for 3 h. Immunoblots shown are representative of three independent experiments. c,e,f , Pro-inflammatory cytokine IL-6 and TNF levels in cell supernatants of iBMDMs pre-incubated 3 h with SCA1, SCA1-NC or the respective derivatives over a dose response (0.313–80 μM) followed by 6 h LPS stimulation (100 ng/ml) ( n = 4). For measurement of pro-inflammatory cytokine IL-1β levels in cell supernatants, iBMDMs were pre-treated with LPS (100 ng/ml) for 3 h followed by treatment with DMSO or SCA9 at the indicated concentrations for 45 min and primed with adenosine triphosphate (ATP, 5 mM) for 45 min ( n = 3). Absolute cytokine production as a function of concentration is used to calculate IC 50 values. d , Pro-inflammatory cytokine IL-6 and TNF levels in cell supernatants of iBMDMs treated 3 h with SCA1 (20 μM) alone or 6 h with LPS (100 ng/ml) alone ( n = 3). g, Phagocytic activity of iBMDMs pre-treated 3 h with SCA1, SCA9, SCA7 or SCA25 (10 μM) followed by 6 h LPS stimulation (100 ng/ml) ( n = 6). h, Relative fold changes in protein abundance between iBMDMs treated with SCA1 (50 μM) for 3 h followed by LPS (100 ng/ml, 15 min) versus LPS alone ( n = 3). Data are mean ± s.e.m. (in d,h ) or s.d. (in c,e-g ). P values calculated using one-way or two-way ANOVA for multiple comparisons or two-tailed Student’s t -tests for unpaired comparisons.
    Anti Phospho Shp1 Tyr564, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/shp1/pmc13070297-321-94-96
    Average 86 stars, based on 1 article reviews
    anti phospho shp1 tyr564 - by Bioz Stars, 2026-09
    86/100 stars

    Images

    1) Product Images from "A druggable redox switch on SHP1 controls macrophage inflammation"

    Article Title: A druggable redox switch on SHP1 controls macrophage inflammation

    Journal: Nature chemical biology

    doi: 10.1038/s41589-026-02163-8

    a, LPS-induced (100 ng/ml) SHP1 Tyr536, Tyr564 and Ser591 phosphorylation in iBMDMs over a time course of 2 h in iBMDMs pre-treated with DMSO or SCA1 (50 μM) for 3 h. Immunoblots shown are representative of three independent experiments. b , LPS-induced (100 ng/ml) STAT3 Tyr705 and Ser727 phosphorylation in iBMDMs over a time course of 2 h in iBMDMs pre-treated with DMSO or SCA1 (50 μM) for 3 h. Immunoblots shown are representative of three independent experiments. c,e,f , Pro-inflammatory cytokine IL-6 and TNF levels in cell supernatants of iBMDMs pre-incubated 3 h with SCA1, SCA1-NC or the respective derivatives over a dose response (0.313–80 μM) followed by 6 h LPS stimulation (100 ng/ml) ( n = 4). For measurement of pro-inflammatory cytokine IL-1β levels in cell supernatants, iBMDMs were pre-treated with LPS (100 ng/ml) for 3 h followed by treatment with DMSO or SCA9 at the indicated concentrations for 45 min and primed with adenosine triphosphate (ATP, 5 mM) for 45 min ( n = 3). Absolute cytokine production as a function of concentration is used to calculate IC 50 values. d , Pro-inflammatory cytokine IL-6 and TNF levels in cell supernatants of iBMDMs treated 3 h with SCA1 (20 μM) alone or 6 h with LPS (100 ng/ml) alone ( n = 3). g, Phagocytic activity of iBMDMs pre-treated 3 h with SCA1, SCA9, SCA7 or SCA25 (10 μM) followed by 6 h LPS stimulation (100 ng/ml) ( n = 6). h, Relative fold changes in protein abundance between iBMDMs treated with SCA1 (50 μM) for 3 h followed by LPS (100 ng/ml, 15 min) versus LPS alone ( n = 3). Data are mean ± s.e.m. (in d,h ) or s.d. (in c,e-g ). P values calculated using one-way or two-way ANOVA for multiple comparisons or two-tailed Student’s t -tests for unpaired comparisons.
    Figure Legend Snippet: a, LPS-induced (100 ng/ml) SHP1 Tyr536, Tyr564 and Ser591 phosphorylation in iBMDMs over a time course of 2 h in iBMDMs pre-treated with DMSO or SCA1 (50 μM) for 3 h. Immunoblots shown are representative of three independent experiments. b , LPS-induced (100 ng/ml) STAT3 Tyr705 and Ser727 phosphorylation in iBMDMs over a time course of 2 h in iBMDMs pre-treated with DMSO or SCA1 (50 μM) for 3 h. Immunoblots shown are representative of three independent experiments. c,e,f , Pro-inflammatory cytokine IL-6 and TNF levels in cell supernatants of iBMDMs pre-incubated 3 h with SCA1, SCA1-NC or the respective derivatives over a dose response (0.313–80 μM) followed by 6 h LPS stimulation (100 ng/ml) ( n = 4). For measurement of pro-inflammatory cytokine IL-1β levels in cell supernatants, iBMDMs were pre-treated with LPS (100 ng/ml) for 3 h followed by treatment with DMSO or SCA9 at the indicated concentrations for 45 min and primed with adenosine triphosphate (ATP, 5 mM) for 45 min ( n = 3). Absolute cytokine production as a function of concentration is used to calculate IC 50 values. d , Pro-inflammatory cytokine IL-6 and TNF levels in cell supernatants of iBMDMs treated 3 h with SCA1 (20 μM) alone or 6 h with LPS (100 ng/ml) alone ( n = 3). g, Phagocytic activity of iBMDMs pre-treated 3 h with SCA1, SCA9, SCA7 or SCA25 (10 μM) followed by 6 h LPS stimulation (100 ng/ml) ( n = 6). h, Relative fold changes in protein abundance between iBMDMs treated with SCA1 (50 μM) for 3 h followed by LPS (100 ng/ml, 15 min) versus LPS alone ( n = 3). Data are mean ± s.e.m. (in d,h ) or s.d. (in c,e-g ). P values calculated using one-way or two-way ANOVA for multiple comparisons or two-tailed Student’s t -tests for unpaired comparisons.

    Techniques Used: Phospho-proteomics, Western Blot, Incubation, Concentration Assay, Activity Assay, Quantitative Proteomics, Two Tailed Test

    Related Articles

    Western Blot:

    Article Title: Tamoxifen Exerts Anticancer Effects on Pituitary Adenoma Progression via Inducing Cell Apoptosis and Inhibiting Cell Migration
    Article Snippet: The suitable treated cells and tumor tissues were harvested and homogenized in the radio immunoprecipitation assay (RIPA) lysis buffer (Solarbio Biotech Co., Ltd. Beijing, China) supplemented with protease and phosphatase inhibitor cocktails (Thremo, Waltham, MA, USA). .. Western blotting was performed as per standard protocols, and the membranes were probed with antibodies targeting p-JAK1 (74129, Rt, 1:500), JAK1 (29261, Rt, 1:1000), p-STAT6 (56554, Rt, 1:500), p-PI3K (17366, Rt, 1:500), PI3K (4249, Rt, 1:1000), p-AKT (4060, Rt, 1:500), AKT (4685, Rt, 1:1000), p53 (48818, Ms, 1:1000), Bax (14796, Rt, 1:1000), p-NF-κB p65 (3033, Rt, 1:500), NF-κB p65 (8242, Rt, 1:1000), p-IκBα (2859, Rt, 1:500), IκBα (4814, Ms, 1:1000), p-IKKα/β (2697, Rt, 1:500), IKKα (11930, Ms, 1:1000), IKKβ (8943, Rt, 1:1000), p-SHP1 (8849, Rt, 1:500), SHP1 (26516, Rt, 1:1000), p-SHP2 (5431, Rt, 1:500), SHP2 (3397, Rt, 1:1000), SIRPα (47027, Rt, 1:1000) (Cell Signaling, Danvers, MA, USA), STAT6 (YT4454, Rt, 1:1000), MyD88 (YM33092, Ms, 1:1000) (Immunway, Plano, MA, USA), GAPDH (10494-1-AP, Ms, 1:1000), INOS (22226-1-AP, Rt, 1:1000) (Proteintech, Wuhan, Hubei, China), Bcl-2 (ab32124, Rt, 1:1000) (Abcam, Cambridge, MA, USA) and TLR4 (sc-293072, Ms, 1:1000) (santa cruz biotechnology, Silicon Valley, CA, USA)positive bands were detected using an ECL Kit (CWBIO, Beijing, China) and the Tanon Chemiluminescence Image Analysis System (Shanghai, China). .. The total RNA of RAW 264.7 cells was isolated using Trizol (Thermo, Waltham, MA, USA) according to the manufacturer’s protocol, and reverse-transcribed into cDNA using MonScriptTM 5× RTIII All-in-One Mix (Monad Biotech Co., Ltd., Wuhan, Hubei, China).

    Incubation:

    Article Title: Knocking down B7H3 expression enhances cell proliferation of SHEDs via the SHP1/AKT signal axis.
    Article Snippet: B7H3 is a member of B7 family of immunoregulatory transmembrane glycoproteins associated with maintaining immune tolerance, tumor cell proliferation, migration, invasion and metabolism, drug resistance, and stem cell differentiation.. Neural crest-derived Multipotent Stem Cells (MSCs) from the dental pulp has become a good choice for tissue regeneration because it is easily obtainable and has strong regeneration potentials.. Although there have been many studies investigating the role of B7H3 in cancer cells and immune cells, its role in the dental pulp stem cells regeneration is unknown.

    Article Title: TREM2 aggravates sepsis by inhibiting fatty acid oxidation via the SHP1/BTK axis
    Article Snippet: .. Membranes were blocked in PBS-Tween20 (pH 7.4, 0.5% Tween20) containing 5% BSA for 1 hour at room temperature (RT) and then incubated overnight at 4 °C with primary antibodies against TREM2 (Cat. #MABN755, Merck), BTK (Cat. #8547, CST), p-BTK (Cat. #87141S, CST), SHP1 (Cat. #3759, CST), p-SHP1 (Cat. #8849, CST), AMPK (Cat. # 5831T, CST), p-AMPK (Cat. #2535T, CST), STAT6 (Cat. #5397S, CST), p-STAT6 (Cat. #56554S, CST), HK2 (Cat. #2867S, CST), PKM2 (Cat. #4053S, CST), CPTI (Cat. #ab128568, ABCAM), PPAR (Cat. ab215270, ABCAM), PPAR (Cat. #ab23673, ABCAM), PPAR (Cat. #ab45036, ABCAM), PGC1 (Cat. ab54481, ABCAM), PGC1 (Cat. #ab176328, ABCAM), HA-Tag (Cat. #3724S, CST), Flag-Tag Cat. (#2368S, CST), Myc-Tag (Cat. #2276, CST) and β-actin (Cat. #ab6276, ABCAM). .. Then the membranes were incubated with appropriate horseradish peroxidase (HRP)-conjugated secondary antibodies at RT for 1 hour, followed by the visualization with GE Image Quant LAS 500 using an ECL kit (Fdbio Science).

    Chromatin Immunoprecipitation:

    Article Title: Temporal photoproximity labeling of ligand-activated EGFR neighborhoods using MultiMap.
    Article Snippet: .. 3 nature portfolio | reporting sum m ary April 2023 Materials & experimental systems n/a Involved in the study Antibodies Eukaryotic cell lines Palaeontology and archaeology Animals and other organisms Clinical data Dual use research of concern Plants Methods n/a Involved in the study ChIP-seq Flow cytometry MRI-based neuroimaging Antibodies Antibodies used Antibodies were purchased including: EGFR (Thermo Scientific, MA5-13319; Cell Signaling Technology, 4267, 2239, 2256), Rab11a (Cell Signaling Technology, 2413), STAT2 (Cell Signaling Technology, 72604), EPS15 (Cell Signaling Technology, 12460), SHP1 (Cell Signaling Technology, 26516), ITGA2 (Bethyl Laboratories, A305-211A-T; Cell Signaling Technology, 88228), Dynamin I/II (Cell Signaling Technology, 2342), SRC (Cell Signaling Technology, 2109), ARF6 (Cell Signaling Technology, 5740), PTPRF (Cell Signaling Technology, 61611), β-actin (Santa Cruz Biotechnology, sc-47778), CD44 (Cell Signaling Technology, 3578), Tid1 (Cell Signaling Technology, 4775), β-catenin (Cell Signaling Technology, 8480), GRB2 (Cell Signaling Technology, 3972), STAT3 (Cell Signaling Technology, 12640), Phospho-EGFR (Tyr1045) (Cell Signaling Technology, 2237), Phospho-EGFR (Tyr1086) (Cell Signaling Technology, 2220S), Phospho-EGFR (Tyr845) (Cell Signaling Technology, 2231), Phospho-EGFR (Tyr992) (Cell Signaling Technology 2235), Phospho-EGFR (Tyr1068) (Cell Signaling Technology, 3777), Phospho-EGFR (Tyr978) (Cell Signaling Technology, 3790), Phospho-EGFR (Tyr1173) (Cell Signaling Technology, 4757, 2244), Phospho-p44/42 MAPK (pERK) (Cell Signaling Technology, 4370, 9101), P44/42 MAPK (ERK1/2) (Cell Signaling Technology, 4695), Phospho-Akt (S473) (Cell Signaling Technology, 4058), Phospho-MEK (S217/221) (Cell Signaling Technology, 9154), Phospho-PLCy (Y783) (Cell Signaling Technology, 2821), Akt (Cell Signaling Technology, 4691), Phospho-EGFR (Y1068) Fluorescein-conjugated Antibody (R&D Systems, IC3570F), Phospho-EGFR Pathway Antibody panel (Cell Signaling Technology, 9789). ..

    Flow Cytometry:

    Article Title: Temporal photoproximity labeling of ligand-activated EGFR neighborhoods using MultiMap.
    Article Snippet: .. 3 nature portfolio | reporting sum m ary April 2023 Materials & experimental systems n/a Involved in the study Antibodies Eukaryotic cell lines Palaeontology and archaeology Animals and other organisms Clinical data Dual use research of concern Plants Methods n/a Involved in the study ChIP-seq Flow cytometry MRI-based neuroimaging Antibodies Antibodies used Antibodies were purchased including: EGFR (Thermo Scientific, MA5-13319; Cell Signaling Technology, 4267, 2239, 2256), Rab11a (Cell Signaling Technology, 2413), STAT2 (Cell Signaling Technology, 72604), EPS15 (Cell Signaling Technology, 12460), SHP1 (Cell Signaling Technology, 26516), ITGA2 (Bethyl Laboratories, A305-211A-T; Cell Signaling Technology, 88228), Dynamin I/II (Cell Signaling Technology, 2342), SRC (Cell Signaling Technology, 2109), ARF6 (Cell Signaling Technology, 5740), PTPRF (Cell Signaling Technology, 61611), β-actin (Santa Cruz Biotechnology, sc-47778), CD44 (Cell Signaling Technology, 3578), Tid1 (Cell Signaling Technology, 4775), β-catenin (Cell Signaling Technology, 8480), GRB2 (Cell Signaling Technology, 3972), STAT3 (Cell Signaling Technology, 12640), Phospho-EGFR (Tyr1045) (Cell Signaling Technology, 2237), Phospho-EGFR (Tyr1086) (Cell Signaling Technology, 2220S), Phospho-EGFR (Tyr845) (Cell Signaling Technology, 2231), Phospho-EGFR (Tyr992) (Cell Signaling Technology 2235), Phospho-EGFR (Tyr1068) (Cell Signaling Technology, 3777), Phospho-EGFR (Tyr978) (Cell Signaling Technology, 3790), Phospho-EGFR (Tyr1173) (Cell Signaling Technology, 4757, 2244), Phospho-p44/42 MAPK (pERK) (Cell Signaling Technology, 4370, 9101), P44/42 MAPK (ERK1/2) (Cell Signaling Technology, 4695), Phospho-Akt (S473) (Cell Signaling Technology, 4058), Phospho-MEK (S217/221) (Cell Signaling Technology, 9154), Phospho-PLCy (Y783) (Cell Signaling Technology, 2821), Akt (Cell Signaling Technology, 4691), Phospho-EGFR (Y1068) Fluorescein-conjugated Antibody (R&D Systems, IC3570F), Phospho-EGFR Pathway Antibody panel (Cell Signaling Technology, 9789). ..

    Magnetic Resonance Imaging:

    Article Title: Temporal photoproximity labeling of ligand-activated EGFR neighborhoods using MultiMap.
    Article Snippet: .. 3 nature portfolio | reporting sum m ary April 2023 Materials & experimental systems n/a Involved in the study Antibodies Eukaryotic cell lines Palaeontology and archaeology Animals and other organisms Clinical data Dual use research of concern Plants Methods n/a Involved in the study ChIP-seq Flow cytometry MRI-based neuroimaging Antibodies Antibodies used Antibodies were purchased including: EGFR (Thermo Scientific, MA5-13319; Cell Signaling Technology, 4267, 2239, 2256), Rab11a (Cell Signaling Technology, 2413), STAT2 (Cell Signaling Technology, 72604), EPS15 (Cell Signaling Technology, 12460), SHP1 (Cell Signaling Technology, 26516), ITGA2 (Bethyl Laboratories, A305-211A-T; Cell Signaling Technology, 88228), Dynamin I/II (Cell Signaling Technology, 2342), SRC (Cell Signaling Technology, 2109), ARF6 (Cell Signaling Technology, 5740), PTPRF (Cell Signaling Technology, 61611), β-actin (Santa Cruz Biotechnology, sc-47778), CD44 (Cell Signaling Technology, 3578), Tid1 (Cell Signaling Technology, 4775), β-catenin (Cell Signaling Technology, 8480), GRB2 (Cell Signaling Technology, 3972), STAT3 (Cell Signaling Technology, 12640), Phospho-EGFR (Tyr1045) (Cell Signaling Technology, 2237), Phospho-EGFR (Tyr1086) (Cell Signaling Technology, 2220S), Phospho-EGFR (Tyr845) (Cell Signaling Technology, 2231), Phospho-EGFR (Tyr992) (Cell Signaling Technology 2235), Phospho-EGFR (Tyr1068) (Cell Signaling Technology, 3777), Phospho-EGFR (Tyr978) (Cell Signaling Technology, 3790), Phospho-EGFR (Tyr1173) (Cell Signaling Technology, 4757, 2244), Phospho-p44/42 MAPK (pERK) (Cell Signaling Technology, 4370, 9101), P44/42 MAPK (ERK1/2) (Cell Signaling Technology, 4695), Phospho-Akt (S473) (Cell Signaling Technology, 4058), Phospho-MEK (S217/221) (Cell Signaling Technology, 9154), Phospho-PLCy (Y783) (Cell Signaling Technology, 2821), Akt (Cell Signaling Technology, 4691), Phospho-EGFR (Y1068) Fluorescein-conjugated Antibody (R&D Systems, IC3570F), Phospho-EGFR Pathway Antibody panel (Cell Signaling Technology, 9789). ..

    other:

    Article Title: JMJD4-demethylated RIG-I prevents hepatic steatosis and carcinogenesis
    Article Snippet: Antibodies speci c to RIG-I (3743), pSTAT3 Y705 (4113), STAT3 (9139), JAK1 (3344), pJAK2 (3771), JAK2 (3230), SHP1 (3759), SHP2 (3397), SOCS1 (3950), SOCS3 (52113), PIAS1 (3550), PIAS3 (4164), pACC (11818), ACC (3676), pAMPKα (50081), AMPKα (5832), cleaved-caspase 3 (9661), pH2AX (9718), and horseradish peroxidasecoupled secondary antibodies (7074 and 7076) were from Cell Signaling Technology (Danvers, MA).



    Similar Products

    shp1  (Purdue University Cytometry)
    86
    Purdue University Cytometry shp1
    Shp1, supplied by Purdue University Cytometry, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/shp1/shp1/pm42093559-70-41-10
    Average 86 stars, based on 1 article reviews
    shp1 - by Bioz Stars, 2026-09
    86/100 stars
    		  Buy from Supplier
    lentiviral shrna constructs targeting shp  (OriGene)
    94
    OriGene lentiviral shrna constructs targeting shp
    ( A ) <t>Relative</t> <t>SHP-1</t> protein expression in the 19 BCa cell lines examined in this study. ( B ) Expression levels were significantly higher in epithelial-like cells (n = 11) than in intermediate and mesenchymal-like lines (n = 8). Error bars represent the standard error of the mean (SEM).
    Lentiviral Shrna Constructs Targeting Shp, supplied by OriGene, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/shp1/SHP1+(PTPN6)+Human+shRNA+Lentiviral+Particle/pmc13162868-52-0-8
    Average 94 stars, based on 1 article reviews
    lentiviral shrna constructs targeting shp - by Bioz Stars, 2026-09
    94/100 stars
    		  Buy from Supplier
    rabbit polyclonal anti ptpn6  (Proteintech)
    93
    Proteintech rabbit polyclonal anti ptpn6
    ( A ) <t>Relative</t> <t>SHP-1</t> protein expression in the 19 BCa cell lines examined in this study. ( B ) Expression levels were significantly higher in epithelial-like cells (n = 11) than in intermediate and mesenchymal-like lines (n = 8). Error bars represent the standard error of the mean (SEM).
    Rabbit Polyclonal Anti Ptpn6, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/shp1/SHP1+Antibody/10__3390_slash_v18040409-65-81-84
    Average 93 stars, based on 1 article reviews
    rabbit polyclonal anti ptpn6 - by Bioz Stars, 2026-09
    93/100 stars
    		  Buy from Supplier
    anti phospho shp1 tyr564  (Cell Signaling Technology Inc)
    86
    Cell Signaling Technology Inc anti phospho shp1 tyr564
    a, LPS-induced (100 ng/ml) <t>SHP1</t> Tyr536, <t>Tyr564</t> and Ser591 phosphorylation in iBMDMs over a time course of 2 h in iBMDMs pre-treated with DMSO or SCA1 (50 μM) for 3 h. Immunoblots shown are representative of three independent experiments. b , LPS-induced (100 ng/ml) STAT3 Tyr705 and Ser727 phosphorylation in iBMDMs over a time course of 2 h in iBMDMs pre-treated with DMSO or SCA1 (50 μM) for 3 h. Immunoblots shown are representative of three independent experiments. c,e,f , Pro-inflammatory cytokine IL-6 and TNF levels in cell supernatants of iBMDMs pre-incubated 3 h with SCA1, SCA1-NC or the respective derivatives over a dose response (0.313–80 μM) followed by 6 h LPS stimulation (100 ng/ml) ( n = 4). For measurement of pro-inflammatory cytokine IL-1β levels in cell supernatants, iBMDMs were pre-treated with LPS (100 ng/ml) for 3 h followed by treatment with DMSO or SCA9 at the indicated concentrations for 45 min and primed with adenosine triphosphate (ATP, 5 mM) for 45 min ( n = 3). Absolute cytokine production as a function of concentration is used to calculate IC 50 values. d , Pro-inflammatory cytokine IL-6 and TNF levels in cell supernatants of iBMDMs treated 3 h with SCA1 (20 μM) alone or 6 h with LPS (100 ng/ml) alone ( n = 3). g, Phagocytic activity of iBMDMs pre-treated 3 h with SCA1, SCA9, SCA7 or SCA25 (10 μM) followed by 6 h LPS stimulation (100 ng/ml) ( n = 6). h, Relative fold changes in protein abundance between iBMDMs treated with SCA1 (50 μM) for 3 h followed by LPS (100 ng/ml, 15 min) versus LPS alone ( n = 3). Data are mean ± s.e.m. (in d,h ) or s.d. (in c,e-g ). P values calculated using one-way or two-way ANOVA for multiple comparisons or two-tailed Student’s t -tests for unpaired comparisons.
    Anti Phospho Shp1 Tyr564, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/shp1/pmc13070297-321-94-96
    Average 86 stars, based on 1 article reviews
    anti phospho shp1 tyr564 - by Bioz Stars, 2026-09
    86/100 stars
    		  Buy from Supplier
    anti shp1  (Cell Signaling Technology Inc)
    86
    Cell Signaling Technology Inc anti shp1
    a, LPS-induced (100 ng/ml) <t>SHP1</t> Tyr536, <t>Tyr564</t> and Ser591 phosphorylation in iBMDMs over a time course of 2 h in iBMDMs pre-treated with DMSO or SCA1 (50 μM) for 3 h. Immunoblots shown are representative of three independent experiments. b , LPS-induced (100 ng/ml) STAT3 Tyr705 and Ser727 phosphorylation in iBMDMs over a time course of 2 h in iBMDMs pre-treated with DMSO or SCA1 (50 μM) for 3 h. Immunoblots shown are representative of three independent experiments. c,e,f , Pro-inflammatory cytokine IL-6 and TNF levels in cell supernatants of iBMDMs pre-incubated 3 h with SCA1, SCA1-NC or the respective derivatives over a dose response (0.313–80 μM) followed by 6 h LPS stimulation (100 ng/ml) ( n = 4). For measurement of pro-inflammatory cytokine IL-1β levels in cell supernatants, iBMDMs were pre-treated with LPS (100 ng/ml) for 3 h followed by treatment with DMSO or SCA9 at the indicated concentrations for 45 min and primed with adenosine triphosphate (ATP, 5 mM) for 45 min ( n = 3). Absolute cytokine production as a function of concentration is used to calculate IC 50 values. d , Pro-inflammatory cytokine IL-6 and TNF levels in cell supernatants of iBMDMs treated 3 h with SCA1 (20 μM) alone or 6 h with LPS (100 ng/ml) alone ( n = 3). g, Phagocytic activity of iBMDMs pre-treated 3 h with SCA1, SCA9, SCA7 or SCA25 (10 μM) followed by 6 h LPS stimulation (100 ng/ml) ( n = 6). h, Relative fold changes in protein abundance between iBMDMs treated with SCA1 (50 μM) for 3 h followed by LPS (100 ng/ml, 15 min) versus LPS alone ( n = 3). Data are mean ± s.e.m. (in d,h ) or s.d. (in c,e-g ). P values calculated using one-way or two-way ANOVA for multiple comparisons or two-tailed Student’s t -tests for unpaired comparisons.
    Anti Shp1, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/shp1/pmc13070297-321-78-79
    Average 86 stars, based on 1 article reviews
    anti shp1 - by Bioz Stars, 2026-09
    86/100 stars
    		  Buy from Supplier
    shp1 sirna  (Santa Cruz Biotechnology)
    93
    Santa Cruz Biotechnology shp1 sirna
    a, LPS-induced (100 ng/ml) <t>SHP1</t> Tyr536, <t>Tyr564</t> and Ser591 phosphorylation in iBMDMs over a time course of 2 h in iBMDMs pre-treated with DMSO or SCA1 (50 μM) for 3 h. Immunoblots shown are representative of three independent experiments. b , LPS-induced (100 ng/ml) STAT3 Tyr705 and Ser727 phosphorylation in iBMDMs over a time course of 2 h in iBMDMs pre-treated with DMSO or SCA1 (50 μM) for 3 h. Immunoblots shown are representative of three independent experiments. c,e,f , Pro-inflammatory cytokine IL-6 and TNF levels in cell supernatants of iBMDMs pre-incubated 3 h with SCA1, SCA1-NC or the respective derivatives over a dose response (0.313–80 μM) followed by 6 h LPS stimulation (100 ng/ml) ( n = 4). For measurement of pro-inflammatory cytokine IL-1β levels in cell supernatants, iBMDMs were pre-treated with LPS (100 ng/ml) for 3 h followed by treatment with DMSO or SCA9 at the indicated concentrations for 45 min and primed with adenosine triphosphate (ATP, 5 mM) for 45 min ( n = 3). Absolute cytokine production as a function of concentration is used to calculate IC 50 values. d , Pro-inflammatory cytokine IL-6 and TNF levels in cell supernatants of iBMDMs treated 3 h with SCA1 (20 μM) alone or 6 h with LPS (100 ng/ml) alone ( n = 3). g, Phagocytic activity of iBMDMs pre-treated 3 h with SCA1, SCA9, SCA7 or SCA25 (10 μM) followed by 6 h LPS stimulation (100 ng/ml) ( n = 6). h, Relative fold changes in protein abundance between iBMDMs treated with SCA1 (50 μM) for 3 h followed by LPS (100 ng/ml, 15 min) versus LPS alone ( n = 3). Data are mean ± s.e.m. (in d,h ) or s.d. (in c,e-g ). P values calculated using one-way or two-way ANOVA for multiple comparisons or two-tailed Student’s t -tests for unpaired comparisons.
    Shp1 Sirna, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/shp1/SH-PTP1+siRNA/pm41794742-102-20-31
    Average 93 stars, based on 1 article reviews
    shp1 sirna - by Bioz Stars, 2026-09
    93/100 stars
    		  Buy from Supplier
    monoclonal anti shp1  (Cell Signaling Technology Inc)
    94
    Cell Signaling Technology Inc monoclonal anti shp1
    a, LPS-induced (100 ng/ml) <t>SHP1</t> Tyr536, <t>Tyr564</t> and Ser591 phosphorylation in iBMDMs over a time course of 2 h in iBMDMs pre-treated with DMSO or SCA1 (50 μM) for 3 h. Immunoblots shown are representative of three independent experiments. b , LPS-induced (100 ng/ml) STAT3 Tyr705 and Ser727 phosphorylation in iBMDMs over a time course of 2 h in iBMDMs pre-treated with DMSO or SCA1 (50 μM) for 3 h. Immunoblots shown are representative of three independent experiments. c,e,f , Pro-inflammatory cytokine IL-6 and TNF levels in cell supernatants of iBMDMs pre-incubated 3 h with SCA1, SCA1-NC or the respective derivatives over a dose response (0.313–80 μM) followed by 6 h LPS stimulation (100 ng/ml) ( n = 4). For measurement of pro-inflammatory cytokine IL-1β levels in cell supernatants, iBMDMs were pre-treated with LPS (100 ng/ml) for 3 h followed by treatment with DMSO or SCA9 at the indicated concentrations for 45 min and primed with adenosine triphosphate (ATP, 5 mM) for 45 min ( n = 3). Absolute cytokine production as a function of concentration is used to calculate IC 50 values. d , Pro-inflammatory cytokine IL-6 and TNF levels in cell supernatants of iBMDMs treated 3 h with SCA1 (20 μM) alone or 6 h with LPS (100 ng/ml) alone ( n = 3). g, Phagocytic activity of iBMDMs pre-treated 3 h with SCA1, SCA9, SCA7 or SCA25 (10 μM) followed by 6 h LPS stimulation (100 ng/ml) ( n = 6). h, Relative fold changes in protein abundance between iBMDMs treated with SCA1 (50 μM) for 3 h followed by LPS (100 ng/ml, 15 min) versus LPS alone ( n = 3). Data are mean ± s.e.m. (in d,h ) or s.d. (in c,e-g ). P values calculated using one-way or two-way ANOVA for multiple comparisons or two-tailed Student’s t -tests for unpaired comparisons.
    Monoclonal Anti Shp1, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/shp1/SHP-1+Rabbit+mAb/pm41771840-235-38-68
    Average 94 stars, based on 1 article reviews
    monoclonal anti shp1 - by Bioz Stars, 2026-09
    94/100 stars
    		  Buy from Supplier
    t shp1  (Cell Signaling Technology Inc)
    94
    Cell Signaling Technology Inc t shp1
    a, LPS-induced (100 ng/ml) <t>SHP1</t> Tyr536, <t>Tyr564</t> and Ser591 phosphorylation in iBMDMs over a time course of 2 h in iBMDMs pre-treated with DMSO or SCA1 (50 μM) for 3 h. Immunoblots shown are representative of three independent experiments. b , LPS-induced (100 ng/ml) STAT3 Tyr705 and Ser727 phosphorylation in iBMDMs over a time course of 2 h in iBMDMs pre-treated with DMSO or SCA1 (50 μM) for 3 h. Immunoblots shown are representative of three independent experiments. c,e,f , Pro-inflammatory cytokine IL-6 and TNF levels in cell supernatants of iBMDMs pre-incubated 3 h with SCA1, SCA1-NC or the respective derivatives over a dose response (0.313–80 μM) followed by 6 h LPS stimulation (100 ng/ml) ( n = 4). For measurement of pro-inflammatory cytokine IL-1β levels in cell supernatants, iBMDMs were pre-treated with LPS (100 ng/ml) for 3 h followed by treatment with DMSO or SCA9 at the indicated concentrations for 45 min and primed with adenosine triphosphate (ATP, 5 mM) for 45 min ( n = 3). Absolute cytokine production as a function of concentration is used to calculate IC 50 values. d , Pro-inflammatory cytokine IL-6 and TNF levels in cell supernatants of iBMDMs treated 3 h with SCA1 (20 μM) alone or 6 h with LPS (100 ng/ml) alone ( n = 3). g, Phagocytic activity of iBMDMs pre-treated 3 h with SCA1, SCA9, SCA7 or SCA25 (10 μM) followed by 6 h LPS stimulation (100 ng/ml) ( n = 6). h, Relative fold changes in protein abundance between iBMDMs treated with SCA1 (50 μM) for 3 h followed by LPS (100 ng/ml, 15 min) versus LPS alone ( n = 3). Data are mean ± s.e.m. (in d,h ) or s.d. (in c,e-g ). P values calculated using one-way or two-way ANOVA for multiple comparisons or two-tailed Student’s t -tests for unpaired comparisons.
    T Shp1, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/shp1/SHP-1+Rabbit+mAb/pm41721390-55-110-111
    Average 94 stars, based on 1 article reviews
    t shp1 - by Bioz Stars, 2026-09
    94/100 stars
    		  Buy from Supplier
    blotting analysis with anti shp1  (Cell Signaling Technology Inc)
    95
    Cell Signaling Technology Inc blotting analysis with anti shp1
    a, LPS-induced (100 ng/ml) <t>SHP1</t> Tyr536, <t>Tyr564</t> and Ser591 phosphorylation in iBMDMs over a time course of 2 h in iBMDMs pre-treated with DMSO or SCA1 (50 μM) for 3 h. Immunoblots shown are representative of three independent experiments. b , LPS-induced (100 ng/ml) STAT3 Tyr705 and Ser727 phosphorylation in iBMDMs over a time course of 2 h in iBMDMs pre-treated with DMSO or SCA1 (50 μM) for 3 h. Immunoblots shown are representative of three independent experiments. c,e,f , Pro-inflammatory cytokine IL-6 and TNF levels in cell supernatants of iBMDMs pre-incubated 3 h with SCA1, SCA1-NC or the respective derivatives over a dose response (0.313–80 μM) followed by 6 h LPS stimulation (100 ng/ml) ( n = 4). For measurement of pro-inflammatory cytokine IL-1β levels in cell supernatants, iBMDMs were pre-treated with LPS (100 ng/ml) for 3 h followed by treatment with DMSO or SCA9 at the indicated concentrations for 45 min and primed with adenosine triphosphate (ATP, 5 mM) for 45 min ( n = 3). Absolute cytokine production as a function of concentration is used to calculate IC 50 values. d , Pro-inflammatory cytokine IL-6 and TNF levels in cell supernatants of iBMDMs treated 3 h with SCA1 (20 μM) alone or 6 h with LPS (100 ng/ml) alone ( n = 3). g, Phagocytic activity of iBMDMs pre-treated 3 h with SCA1, SCA9, SCA7 or SCA25 (10 μM) followed by 6 h LPS stimulation (100 ng/ml) ( n = 6). h, Relative fold changes in protein abundance between iBMDMs treated with SCA1 (50 μM) for 3 h followed by LPS (100 ng/ml, 15 min) versus LPS alone ( n = 3). Data are mean ± s.e.m. (in d,h ) or s.d. (in c,e-g ). P values calculated using one-way or two-way ANOVA for multiple comparisons or two-tailed Student’s t -tests for unpaired comparisons.
    Blotting Analysis With Anti Shp1, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/shp1/SHP-1+Rabbit+mAb/bio_rxiv__64898__2026__02__19__706790-272-31-35
    Average 95 stars, based on 1 article reviews
    blotting analysis with anti shp1 - by Bioz Stars, 2026-09
    95/100 stars
    		  Buy from Supplier

    Image Search Results


    ( A ) Relative SHP-1 protein expression in the 19 BCa cell lines examined in this study. ( B ) Expression levels were significantly higher in epithelial-like cells (n = 11) than in intermediate and mesenchymal-like lines (n = 8). Error bars represent the standard error of the mean (SEM).

    Journal: Cancers

    Article Title: Evidence for a Tumor-Suppressive Role of SHP-1 in EMT Regulation in Bladder Cancer Cells

    doi: 10.3390/cancers18091401

    Figure Lengend Snippet: ( A ) Relative SHP-1 protein expression in the 19 BCa cell lines examined in this study. ( B ) Expression levels were significantly higher in epithelial-like cells (n = 11) than in intermediate and mesenchymal-like lines (n = 8). Error bars represent the standard error of the mean (SEM).

    Article Snippet: Lentiviral shRNA constructs targeting SHP-1 were obtained from Origene (Rockville, MD, USA), and the manufacturer’s protocol was used to establish stable cell lines for each construct.

    Techniques: Expressing

    ( A ) SHP-1 protein expression in bladder tissue was significantly lower in muscle-invasive (MI, n = 8) tumor than in non-muscle-invasive (NMI, n = 8) and urothelial tissue with no residual disease (NRD, n = 10). ( B ) Examples of DAB and corresponding H&E staining in the bladder tissues examined in this study. The error bars represent the interquartile range.

    Journal: Cancers

    Article Title: Evidence for a Tumor-Suppressive Role of SHP-1 in EMT Regulation in Bladder Cancer Cells

    doi: 10.3390/cancers18091401

    Figure Lengend Snippet: ( A ) SHP-1 protein expression in bladder tissue was significantly lower in muscle-invasive (MI, n = 8) tumor than in non-muscle-invasive (NMI, n = 8) and urothelial tissue with no residual disease (NRD, n = 10). ( B ) Examples of DAB and corresponding H&E staining in the bladder tissues examined in this study. The error bars represent the interquartile range.

    Article Snippet: Lentiviral shRNA constructs targeting SHP-1 were obtained from Origene (Rockville, MD, USA), and the manufacturer’s protocol was used to establish stable cell lines for each construct.

    Techniques: Expressing, Staining

    Correlation plots (n = 19) of SHP-1 protein expression with the EMT markers E-cadherin, N-cadherin, and Vimentin. Gray areas represent the 95%CI. Representative Western blot images: from the BCa cell lines EJ and HT-1376, the first lane of each pair corresponds to the protein indicated above each lane, and the second corresponds to the total protein detected for the same lane.

    Journal: Cancers

    Article Title: Evidence for a Tumor-Suppressive Role of SHP-1 in EMT Regulation in Bladder Cancer Cells

    doi: 10.3390/cancers18091401

    Figure Lengend Snippet: Correlation plots (n = 19) of SHP-1 protein expression with the EMT markers E-cadherin, N-cadherin, and Vimentin. Gray areas represent the 95%CI. Representative Western blot images: from the BCa cell lines EJ and HT-1376, the first lane of each pair corresponds to the protein indicated above each lane, and the second corresponds to the total protein detected for the same lane.

    Article Snippet: Lentiviral shRNA constructs targeting SHP-1 were obtained from Origene (Rockville, MD, USA), and the manufacturer’s protocol was used to establish stable cell lines for each construct.

    Techniques: Expressing, Western Blot

    ( A ) SHP-1 protein expression following transduction with SHP-1 shRNA (shSHP-1) or SHP-1 cDNA (+SHP-1) and corresponding negative controls (NC): CUBIII n = 6, RT-112 n = 7, TCCSUP n = 4, UM-UC-3 n = 6. ( B ) Representative Western blot images: the first lane of each pair corresponds to SHP-1, and the second corresponds to the total protein detected for the same lane. Error bars represent the SEM. ( C ) Relative proliferation rates of BCa cells transduced with SHP-1 shRNA (shSHP-1) or SHP-1 cDNA (+SHP-1) and corresponding negative controls (NC): CUBIII n = 5, RT-112 n = 5, TCCSUP n = 9, UM-UC-3 n = 5. Error bars represent the SEM.

    Journal: Cancers

    Article Title: Evidence for a Tumor-Suppressive Role of SHP-1 in EMT Regulation in Bladder Cancer Cells

    doi: 10.3390/cancers18091401

    Figure Lengend Snippet: ( A ) SHP-1 protein expression following transduction with SHP-1 shRNA (shSHP-1) or SHP-1 cDNA (+SHP-1) and corresponding negative controls (NC): CUBIII n = 6, RT-112 n = 7, TCCSUP n = 4, UM-UC-3 n = 6. ( B ) Representative Western blot images: the first lane of each pair corresponds to SHP-1, and the second corresponds to the total protein detected for the same lane. Error bars represent the SEM. ( C ) Relative proliferation rates of BCa cells transduced with SHP-1 shRNA (shSHP-1) or SHP-1 cDNA (+SHP-1) and corresponding negative controls (NC): CUBIII n = 5, RT-112 n = 5, TCCSUP n = 9, UM-UC-3 n = 5. Error bars represent the SEM.

    Article Snippet: Lentiviral shRNA constructs targeting SHP-1 were obtained from Origene (Rockville, MD, USA), and the manufacturer’s protocol was used to establish stable cell lines for each construct.

    Techniques: Expressing, Transduction, shRNA, Western Blot

    ( A ) Relative migration rates of BCa cells transduced with SHP-1 shRNA (shSHP-1) or SHP-1 cDNA (+SHP-1) and corresponding negative controls (NC): CUBIII n = 5, RT-112 n = 4, TCCSUP n = 3, UM-UC-3 n = 3. ( B ) Representative images from in vitro migration assays (scale bar = 200 μm). ( C ) Relative invasion rates of BCa cells transduced with SHP-1 shRNA (shSHP-1) or SHP-1 cDNA (+SHP-1) and corresponding negative controls (NC): CUBIII n = 3, RT-112 n = 5, TCCSUP n = 3, UM-UC-3 n = 3. ( D ) Representative images from in vitro invasion assays (scale bar = 200 μm). Error bars represent the SEM.

    Journal: Cancers

    Article Title: Evidence for a Tumor-Suppressive Role of SHP-1 in EMT Regulation in Bladder Cancer Cells

    doi: 10.3390/cancers18091401

    Figure Lengend Snippet: ( A ) Relative migration rates of BCa cells transduced with SHP-1 shRNA (shSHP-1) or SHP-1 cDNA (+SHP-1) and corresponding negative controls (NC): CUBIII n = 5, RT-112 n = 4, TCCSUP n = 3, UM-UC-3 n = 3. ( B ) Representative images from in vitro migration assays (scale bar = 200 μm). ( C ) Relative invasion rates of BCa cells transduced with SHP-1 shRNA (shSHP-1) or SHP-1 cDNA (+SHP-1) and corresponding negative controls (NC): CUBIII n = 3, RT-112 n = 5, TCCSUP n = 3, UM-UC-3 n = 3. ( D ) Representative images from in vitro invasion assays (scale bar = 200 μm). Error bars represent the SEM.

    Article Snippet: Lentiviral shRNA constructs targeting SHP-1 were obtained from Origene (Rockville, MD, USA), and the manufacturer’s protocol was used to establish stable cell lines for each construct.

    Techniques: Migration, Transduction, shRNA, In Vitro

    Significant gene sets resulting from GSEA of RNA sequence data comparing the transduced BCa lines with high-SHP-1-expressing lines versus low-SHP-1-expressing lines (q-value < 0.1).

    Journal: Cancers

    Article Title: Evidence for a Tumor-Suppressive Role of SHP-1 in EMT Regulation in Bladder Cancer Cells

    doi: 10.3390/cancers18091401

    Figure Lengend Snippet: Significant gene sets resulting from GSEA of RNA sequence data comparing the transduced BCa lines with high-SHP-1-expressing lines versus low-SHP-1-expressing lines (q-value < 0.1).

    Article Snippet: Lentiviral shRNA constructs targeting SHP-1 were obtained from Origene (Rockville, MD, USA), and the manufacturer’s protocol was used to establish stable cell lines for each construct.

    Techniques: Sequencing, Expressing

    Relative expression of pAkt/Akt in BCa cells transduced with SHP-1 shRNA (shSHP-1) or SHP-1 cDNA (+SHP-1) and corresponding negative controls (NC): RT-112 n = 7 and TCCSUP n = 8. Representative Western blot images: the first lane of each pair corresponds to Akt or pAkt (ser473), and the second corresponds to the total protein detected for the same lane. Error bars represent the SEM.

    Journal: Cancers

    Article Title: Evidence for a Tumor-Suppressive Role of SHP-1 in EMT Regulation in Bladder Cancer Cells

    doi: 10.3390/cancers18091401

    Figure Lengend Snippet: Relative expression of pAkt/Akt in BCa cells transduced with SHP-1 shRNA (shSHP-1) or SHP-1 cDNA (+SHP-1) and corresponding negative controls (NC): RT-112 n = 7 and TCCSUP n = 8. Representative Western blot images: the first lane of each pair corresponds to Akt or pAkt (ser473), and the second corresponds to the total protein detected for the same lane. Error bars represent the SEM.

    Article Snippet: Lentiviral shRNA constructs targeting SHP-1 were obtained from Origene (Rockville, MD, USA), and the manufacturer’s protocol was used to establish stable cell lines for each construct.

    Techniques: Expressing, Transduction, shRNA, Western Blot

    a, LPS-induced (100 ng/ml) SHP1 Tyr536, Tyr564 and Ser591 phosphorylation in iBMDMs over a time course of 2 h in iBMDMs pre-treated with DMSO or SCA1 (50 μM) for 3 h. Immunoblots shown are representative of three independent experiments. b , LPS-induced (100 ng/ml) STAT3 Tyr705 and Ser727 phosphorylation in iBMDMs over a time course of 2 h in iBMDMs pre-treated with DMSO or SCA1 (50 μM) for 3 h. Immunoblots shown are representative of three independent experiments. c,e,f , Pro-inflammatory cytokine IL-6 and TNF levels in cell supernatants of iBMDMs pre-incubated 3 h with SCA1, SCA1-NC or the respective derivatives over a dose response (0.313–80 μM) followed by 6 h LPS stimulation (100 ng/ml) ( n = 4). For measurement of pro-inflammatory cytokine IL-1β levels in cell supernatants, iBMDMs were pre-treated with LPS (100 ng/ml) for 3 h followed by treatment with DMSO or SCA9 at the indicated concentrations for 45 min and primed with adenosine triphosphate (ATP, 5 mM) for 45 min ( n = 3). Absolute cytokine production as a function of concentration is used to calculate IC 50 values. d , Pro-inflammatory cytokine IL-6 and TNF levels in cell supernatants of iBMDMs treated 3 h with SCA1 (20 μM) alone or 6 h with LPS (100 ng/ml) alone ( n = 3). g, Phagocytic activity of iBMDMs pre-treated 3 h with SCA1, SCA9, SCA7 or SCA25 (10 μM) followed by 6 h LPS stimulation (100 ng/ml) ( n = 6). h, Relative fold changes in protein abundance between iBMDMs treated with SCA1 (50 μM) for 3 h followed by LPS (100 ng/ml, 15 min) versus LPS alone ( n = 3). Data are mean ± s.e.m. (in d,h ) or s.d. (in c,e-g ). P values calculated using one-way or two-way ANOVA for multiple comparisons or two-tailed Student’s t -tests for unpaired comparisons.

    Journal: Nature chemical biology

    Article Title: A druggable redox switch on SHP1 controls macrophage inflammation

    doi: 10.1038/s41589-026-02163-8

    Figure Lengend Snippet: a, LPS-induced (100 ng/ml) SHP1 Tyr536, Tyr564 and Ser591 phosphorylation in iBMDMs over a time course of 2 h in iBMDMs pre-treated with DMSO or SCA1 (50 μM) for 3 h. Immunoblots shown are representative of three independent experiments. b , LPS-induced (100 ng/ml) STAT3 Tyr705 and Ser727 phosphorylation in iBMDMs over a time course of 2 h in iBMDMs pre-treated with DMSO or SCA1 (50 μM) for 3 h. Immunoblots shown are representative of three independent experiments. c,e,f , Pro-inflammatory cytokine IL-6 and TNF levels in cell supernatants of iBMDMs pre-incubated 3 h with SCA1, SCA1-NC or the respective derivatives over a dose response (0.313–80 μM) followed by 6 h LPS stimulation (100 ng/ml) ( n = 4). For measurement of pro-inflammatory cytokine IL-1β levels in cell supernatants, iBMDMs were pre-treated with LPS (100 ng/ml) for 3 h followed by treatment with DMSO or SCA9 at the indicated concentrations for 45 min and primed with adenosine triphosphate (ATP, 5 mM) for 45 min ( n = 3). Absolute cytokine production as a function of concentration is used to calculate IC 50 values. d , Pro-inflammatory cytokine IL-6 and TNF levels in cell supernatants of iBMDMs treated 3 h with SCA1 (20 μM) alone or 6 h with LPS (100 ng/ml) alone ( n = 3). g, Phagocytic activity of iBMDMs pre-treated 3 h with SCA1, SCA9, SCA7 or SCA25 (10 μM) followed by 6 h LPS stimulation (100 ng/ml) ( n = 6). h, Relative fold changes in protein abundance between iBMDMs treated with SCA1 (50 μM) for 3 h followed by LPS (100 ng/ml, 15 min) versus LPS alone ( n = 3). Data are mean ± s.e.m. (in d,h ) or s.d. (in c,e-g ). P values calculated using one-way or two-way ANOVA for multiple comparisons or two-tailed Student’s t -tests for unpaired comparisons.

    Article Snippet: Equal amounts of proteins were resolved using NuPAGE 4–12% Bis-Tris 15-well or 26-well gels (Invitrogen, #NP0336BOX or #WG1403BOX), transferred onto PVDF membranes (Thermo Fisher Scientific, iBlot 2 Gel Transfer Device, #IB21001), and immunoblotted with anti-IRAK1 (Cell Signaling, #4504, rabbit mAb; 1:1000 dilution), anti-phospho-IκBα (Ser32/36) (Cell Signaling, #9246; mouse mAb; 1:1000 dilution), anti-IκBα (Cell Signaling, #9242, rabbit pAb; 1:1000 dilution), anti-phospho-NFκB p65 (Ser536) (Cell Signaling, #3033, rabbit mAb; 1:1000 dilution), anti-NFκB p65 (Cell Signaling, #8242, rabbit mAb; 1:1000 dilution), anti-SHP1 (Cell Signaling, #3759, rabbit mAb; 1:1000 dilution), anti-phospho-SHP1 (Tyr536) (Invitrogen, #PA5–36682, rabbit pAb; 1:1000 dilution), anti-phospho-SHP1 (Tyr564) (Cell Signaling, #8849, rabbit mAb; 1:1000 dilution), anti-phospho-SHP1 (Ser591) (Invitrogen, #PA5–143764, rabbit pAb; 1:1000 dilution), anti-STAT3 (Cell Signaling, #4904, rabbit mAb; 1:1000 dilution), anti-phospho-STAT3 (Tyr705) (Cell Signaling, #9145, rabbit mAb; 1:1000 dilution), anti-phospho-STAT3 (Ser727) (Cell Signaling, #9136, mouse mAb; 1:1000 dilution) and anti-β-actin (Cell Signaling, #3700, mouse mAb; 1:3000 dilution) antibodies, diluted in TBS-T (Boston BioProducts, Inc., #IBB-180X) containing 5% BSA, followed by incubation with horseradish peroxidase-conjugated anti-rabbit or anti-mouse secondary antibodies (Promega, #W4011 or #W4021), diluted 1:10000 in TBS-T containing 5% milk, and visualized using ECL western blotting substrates (Pierce ECL Western Blotting Substrate, #32106).

    Techniques: Phospho-proteomics, Western Blot, Incubation, Concentration Assay, Activity Assay, Quantitative Proteomics, Two Tailed Test